RxDoctor Payments Data

James Morse, MD

Gastroenterology · Portland, MENPI 1679512719

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $442 of the $592 with a category attached, or 74.7%. 9 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.3% of the total. That places this record below the midpoint for gastroenterology clinicians in ME, where the typical reported total is $670.

$592in general payments, 2019–2025

Across 16 payments — averaging $37.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$197
  • Fujifilm Healthcare Americas Corporation$70
  • Sanofi$69
  • E.r. Squibb & Sons, L.L.C.$64
  • Gilead$49
  • AbbVie$46
  • plus $97 from 3 others

What the payments were for

  • Speaking & faculty fees$15025%
  • Food & beverage$44275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$592 in reported general payments places this provider in the 45th percentile of 68 gastroenterology providers in Maine.

See all gastroenterology providers in Maine

Medicare billing

Part B allowed, 2024
$273,850
Medicare patients
283
Services billed
9,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$417,764
Humira(Cf) PenAdalimumab26$173,215
XifaxanRifaximin12$35,653
Mesalamine44$31,439
Balsalazide Disodium14$3,858
Ursodiol11$3,027
Budesonide EcBudesonide11$2,433
Omeprazole70$967
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl77$878
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$819
Famotidine71$791
Pantoprazole Sodium32$707
Sucralfate14$468
Dicyclomine Hcl20$378
LoperamideLoperamide Hcl11$316

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →